Sudocetaxel zendusortide

N/A

Report date: 2024/05/09 15:08:29
NME

Base Information

Drug NameSudocetaxel zendusortide
Drug Alias NameDoceKADocetaxel-KA-peptide conjugateTH-1902TH1902
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionTubulin inhibitorsMitosis inhibitorsTubulin polymerisation inhibitors
TargetsTubulin
Therapy Area/IndicationsSkin MelanomaSolid tumoursProstatic Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesKatana Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesTheratechnologies Inc
Inactive CompaniesN/A
Active IndicationsSkin MelanomaSolid tumoursProstatic Neoplasms +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A